Resolution of D,L-dehydroproline |
| I claim: 1. A method for the preparation of L-3,4-dehydroproline comprising in combination the ... |
|
Quaternary salts as hypoglycemic agents |
| OF THE INVENTION The hypoglycemic agents of the present invention are synthesized by the reaction ... |
|
Pasteurized therapeutically active protein compositions |
| What is claimed is: 1. A method of pasteurizing a composition comprising a thermally sensitive, ... |
|
Method of preparing a high-purity, virus safe, biologically active transferrin preparation |
| We claim: 1. A method of preparing a high-purity, virus-safe biologically active, transferrin ... |
|
Hydrolyzable resin composition and an antifouling coating composition containing the same |
| What is claimed is: 1. A method of preventing marine fouling which comprises applying to a surface ... |
|
Treatment for herpes virus |
| OF THE INVENTION According to the invention, I provide a composition for and method of use of such ... |
|
Microbicidal meta oxy- and thio-substituted phenylanilines |
| What is claimed is: 1. A compound of the formula I, including salts and metal complexes thereof ##ST... |
|
Substituted acyl derivatives of amino acids |
| OF THE INVENTION The invention in its broad aspects includes substituted acyl derivatives of amino ... |
|
|
Process for the preparation of a new-type active substance selectively inhibiting food intake
| Details |
Inventors: Knoll, Jozsef; Nagy, Janos; Kalasz, Huba; Knoll, Berta;
Assignee: Richter Gedeon Vegyeszeti Gyar Rt. (Budapest, HU)
Primary Examiner:
Assistant Examiner:
Attorney, Agent or Firm:
The invention involves isolating a food intake suppressant by subjecting blood serum to ultrafiltration transmitting up to a molecular weight of 30,000 daltons, partially evaporating the filtrate, removing the insoluble part from the concentrate obtained, adding trichloroacetic acid up to a concentration of 5 to 25 weight/volume percent to the liquid phase at a temperature of 0.degree. to 10.degree. C., removing the proteins precipitated, subjecting the obtained solution to chromatography on a gel with a void volume below a molecular weight of 4000 daltons, eluting with a solution of pH 6.0 to 7.0, concentrating the biologically active fractions, chromatographing again on a gel with a void volume below a molecular weight of 4000 daltons, fractionating by elution with water, lyophilizing the active fractions, dissolving the lyophilized fractions in a buffer of pH 8.1 to 8.2, adding trypsin and chymotrypsin to the solution in a substantially identical amount of 0.01 to 0.2 by weight as calculated for the total weight of the lyophilized product, subjecting the mixture to digestion at a temperature of 36.degree. C. to 39.degree. C., preferably with occasionally shaking from 20 to 30 hours, adding after the first 5 hours trypsin and chymotrypsin in a substantially half amount as calculated for the original enzyme quantity and continuing the digestion, then adding trichloroacetic acid to the reaction mixture up to a concentration of 4 to 6 weight/volume percent at a temperature between 0.degree. and 10.degree. C., keeping the mixture at a temperature between -15.degree. C. and 5.degree. C. for 1 to 24 hours, removing the insoluble part, subjecting the reaction mixture to chromatography on a gel with a void volume below a molecular weight of 4000 daltons, fractionating by elution with water and lyophilizing the biologically active fractions. |
|
DETAILED DESCRIPTION What we claim is: 1. A process for isolating a food intake suppressant from human or animal blood serum which comprises subjecting the human and/or animal blood serum to ultrafiltration on a membrane or hollow fiber ultrafilter passing a filtrate containing substances of a molecular weight of at most 50,000 daltons, partially evaporating the filtrate, removing the insoluble part from the concentrate obtained, adding trichloroacetic acid up to a concentration of 5 to 25 weight/volume percent to the liquid phase at a temperature of 0. degree. C. to 10. degree. C. , removing the proteins precipitated, subjecting the obtained solution to chromatography on a gel with an elution solution of pH 6. 0 to 7. 0, concentrating the biologically active fractions, chromatographing again on a gel with a void volume having a molecular weight of 3000 to 4000 daltons, fractionating by elution with water, lyophilizing the active fractions, dissolving the lyophilized fractions in a buffer of pH 8. 1 to 8. 2, adding trypsin and chymotrypsin to the solution in substantially identical amounts of 0. 01 to 0. 2 by weight as calculated for the total weight of the lyophilized product, subjecting the mixture to digestion at a temperature of 36. degree. C. to 39. degree. C. for 20 to 30 hours, adding after the first 5 hours an equal quantity of trypsin and chymotrypsin in a substantially half amount as calculated for the original enzyme quantity and continuing the digestion, then adding trichloroacetic acid to the reaction mixture up to a concentration of 4 to 6 weight/vol. % at a temperature between 0. degree. C. and 10. degree. C. , keeping the mixture at a temperature between -15. degree. C. and 5. degree. C. for 1 to 24 hours, removing the insoluble part, subjecting the reaction mixture to chromatography on a gel with a void volume having a molecular weight of 3000 to 4000 daltons, fractionating by elution with water and lyophilizing the biologically active fractions to yield said food intake suppressant having a molecular weight between 40,000 and 50,000 daltons
|
| Related patents |
|
|
Terminal methionyl bovine growth hormone and its use
According to the present invention, synthetic DNA is provided for a substantial portion of the initial coding sequence of a heterologous gene insert, and optionally, ...
|
|
|
Human immune interferon
The present invention is based upon the discovery that recombinant DNA technology can be used to successfully produce human immune interferon, preferably in direct form, ...
|
|
|
Method for production of an enzyme granulate
I claim: 1. In a process for production of an enzyme granulate which comprises granulating an enzyme composition comprising enzyme, filler, binder, and from 1.5-40% by ...
|
|
|
Process for preparing narasin
The new microorganism of this invention is a biologically pure culture derived from a soil sample collected near the Surinam River, Surinam, South America. The culture ...
|
|
|
Reversible optical waveguide vapor sensor
Accordingly, it is an object of the invention to detect small amounts of a chemical in air and in other gases. Another object is to provide a device for such purpose ...
|
|
|
Biotinidase-resistant biotinylated compound and methods of use thereof
This invention relates to biotinidase-resistant biotinylated compounds containing a chemical fragment having the structure: ##STR2## wherein R.sub.1 and R.sub.3 are ...
|
|
|
Method of recovering shiga-like toxins and vaccines comprising inactivated shiga-like toxin
This invention provides a facile, efficient and reproducible method for recovering biologically active Shiga-like toxins from a sample using an affinity ligand ...
|
|
|
Assays for shiga toxin and shiga-like toxins
OF THE INVENTION The present invention relates to a substantially pure antigenic or peptide protein related to Shiga toxin (ST) or Shiga-like toxins I or II (SLT-II, SLT...
|
|
|
Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
OF THE INVENTION Histologic examination of colonic tissue has revealed no evidence of attachment of E. coli O157:H7 to bovine colonic tissue. The rumen appears to be ...
|
|
|
Feline leukemia virus vaccines
OF THE INVENTION Any immunogenic FeLV protein may be expressed in baculovirus following the methods and techniques described here. For instance, the location and ...
|
|
|